• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 552-58-9 Price $128 / 20mg
    Catalog No.CFN99719Purity>=98%
    Molecular Weight288.25Type of CompoundFlavonoids
    FormulaC15H12O6Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Universiti Kebangsaan Malaysia (Malaysia)
  • Universite Libre de Bruxelles (Belgium)
  • Celltrion Chemical Research Inst... (Korea)
  • Fraunhofer-Institut für Molekul... (Germany)
  • Siksha O Anusandhan University (India)
  • Universidade Federal de Santa Ca... (Brazil)
  • Indian Institute of Science (India)
  • University of Melbourne (Australia)
  • Chulalongkorn University (Thailand)
  • University of the Basque Country (Spain)
  • University of Eastern Finland (Finland)
  • More...
  • Package
    Featured Products
    Ganoderiol F

    Catalog No: CFN99244
    CAS No: 114567-47-4
    Price: $398/5mg
    Decursitin D

    Catalog No: CFN95002
    CAS No: 245446-61-1
    Price: $388/5mg

    Catalog No: CFN99111
    CAS No: 21967-41-9
    Price: $40/20mg

    Catalog No: CFN97135
    CAS No: 66648-43-9
    Price: $288/10mg
    Ginsenoside Re

    Catalog No: CFN99974
    CAS No: 52286-59-6
    Price: $40/20mg
    Biological Activity
    Description: Eriodictyol has vasodilator, anti-inflammatory and antioxidant activities, it is an antagonist of the transient potential vanilloid 1 receptor (TRPV1) receptor. Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance, it attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the blood-retinal barrier (BRB) in early diabetic rats. It may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis.
    Targets: COX | TLR | gp120/CD4 | p38MAPK | ERK | JNK | ROS | IL Receptor | PPAR | PI3K | Akt | TNF-α | VEGFR | NOS | TRPV | EGFR | MEK | ERK
    In vitro:
    BMB Rep. 2013 Dec;46(12):594-9.
    Binding model for eriodictyol to Jun-N terminal kinase and its anti-inflammatory signaling pathway.[Pubmed: 24195792]
    The anti-inflammatory activity of Eriodictyol and its mode of action were investigated.
    Eriodictyol suppressed tumor necrosis factor (mTNF)-α, inducible nitric oxide synthase (miNOS), interleukin (mIL)-6, macrophage inflammatory protein (mMIP)-1, and mMIP-2 cytokine release in LPS-stimulated macrophages. We found that the anti-inflammatory cascade of Eriodictyol is mediated through the Toll-like Receptor (TLR)4/CD14, p38 mitogen-activated protein kinases (MAPK), extracellular-signal-regulated kinase (ERK), Jun-N terminal kinase (JNK), and cyclooxygenase (COX)-2 pathway. Fluorescence quenching and saturation-transfer difference (STD) NMR experiments showed that Eriodictyol exhibits good binding affinity to JNK, 8.79 × 10(5) M(-1). Based on a docking study, we propose a model of Eriodictyol and JNK binding, in which Eriodictyol forms 3 hydrogen bonds with the side chains of Lys55, Met111, and Asp169 in JNK, and in which the hydroxyl groups of the B ring play key roles in binding interactions with JNK.
    Therefore, Eriodictyol may be a potent anti-inflammatory inhibitor of JNK.
    Biol Pharm Bull. 2007 Jan;30(1):32-7.
    The anti-apoptotic and anti-oxidant effect of eriodictyol on UV-induced apoptosis in keratinocytes.[Pubmed: 17202655]
    Recently, considerable scientific and therapeutic interest has focused on the structure and functions of the flavonoids. In a previous study, we suggested that hydroxyl (OH) substitutions on specific carbons in the skeleton of the flavonoids might significantly affect their apoptosis-modulating properties.
    Here, to investigate the effect of various OH substitutions on their diphenylpropane (C6C3C6) skeleton carbons, we selected 10 different flavonoids and assessed their role on UV-induced apoptosis of human keratinocytes, the principal cell type of epidermis. The results showed that 5,7,3',4'-tetrahydroxylflavanone (Eriodictyol) and 3,4'-dihydroxy flavone (3,4'-DHF) had a positive effect on cell proliferation of human HaCaT keratinocytes. Treatment with Eriodictyol in particular resulted in significant suppression of cell death induced by ultraviolet (UV) light, a major skin-damaging agent. We found that Eriodictyol treatment apparently reduced the percentage of apoptotic cells and the cleavage of poly(ADP-ribose) polymerase, concomitant with the repression of caspase-3 activation and reactive oxygen species (ROS) generation. The anti-apoptotic and anti-oxidant effects of Eriodictyol were also confirmed in UV-induced cell death of normal human epidermal keratinocyte (NHEK) cells.
    Taken together, these findings suggest that Eriodictyol can be used to protect keratinocytes from UV-induced damage, implying the presence of a complex structure-activity relationship (SAR) in the differential apoptosis-modulating activities of various flavonoids.
    In vivo:
    Biol Pharm Bull. 2013;36(8):1375-9.
    Effect of eriodictyol on the development of atopic dermatitis-like lesions in ICR mice.[Pubmed: 23902981]
    Atopic dermatitis (AD) is a chronic, allergic, and inflammatory skin disease associated with eczema and dermatitis symptoms. Our previous studies have reported that Eriodictyol extract inhibits immunoglobulin E (IgE)/Ag-induced type I hypersensitivity by suppressing the activation of proinflammatory cytokines, such as interleukin-4 (IL-4), and the expression of ceramide kinase.
    In this study, we investigated the inhibitory effect of Eriodictyol on 2,4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions in ICR mice. Treatment with 2 mg/mL Eriodictyol for DNCB-induced AD-like skin lesions in ICR mice improved scratching behavior and skin severity score. Histological analysis demonstrated that thickening of the skin lesions were significantly reduced in the Eriodictyol-treated group. Also, Eriodictyol suppressed the DNCB-mediated elevation of IgE serum levels.
    These results suggest that Eriodictyol may be a potential therapeutic resource for AD and an adjunctive agent to control itchiness in AD.
    Biochem Pharmacol. 2012 Jul 1;84(1):88-92.
    Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats.[Pubmed: 22484312 ]
    Diabetic retinopathy is a complex disease that has potential involvement of inflammatory and oxidative stress-related pathways in its pathogenesis. We hypothesized that Eriodictyol, one of the most abundant dietary flavonoids, could be effective against diabetic retinopathy, which involves significant oxidative stress and inflammation.
    The aim of the present study was to investigate the effects of Eriodictyol in early retinal and plasma changes of streptozotocin-induced diabetic rats. The effect of Eriodictyol treatment (0.1, 1, 10 mg/kg daily for 10 days) was evaluated by TNF-α, ICAM-1, VEGF, and eNOS protein levels measurement in the retina, plasma lipid peroxidation, and blood-retinal barrier (BRB) integrity. Increased amounts of cytokines, adhesion molecule, and nitric oxide synthase were observed in retina from diabetic rats. Eriodictyol treatment significantly lowered retinal TNF-α, ICAM-1, VEGF, and eNOS in a dose-dependent manner. Further, treatment with Eriodictyol significantly suppressed diabetes-related lipid peroxidation, as well as the BRB breakdown.
    These data demonstrated that Eriodictyol attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the BRB in early diabetic rats.
    Eriodictyol Description
    Source: The fruits of Citrus sinensis (L.) Osbeck
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN92616
    CAS No: 7727-79-9
    Price: $278/20mg
    Arjunglucoside II

    Catalog No: CFN89144
    CAS No: 62369-72-6
    Price: $413/5mg
    Deacetyl ganoderic acid F

    Catalog No: CFN90746
    CAS No: 100665-44-9
    Price: $388/5mg
    Mulberroside F

    Catalog No: CFN90794
    CAS No: 193483-95-3
    Price: $398/10mg

    Catalog No: CFN99025
    CAS No: 101140-06-1
    Price: $418/5mg

    Catalog No: CFN97086
    CAS No: 62949-93-3
    Price: $388/5mg

    Catalog No: CFN96416
    CAS No: 13060-14-5
    Price: $398/5mg

    Catalog No: CFN98174
    CAS No: 31008-19-2
    Price: $128/20mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.4692 mL 17.3461 mL 34.6921 mL 69.3842 mL 86.7303 mL
    5 mM 0.6938 mL 3.4692 mL 6.9384 mL 13.8768 mL 17.3461 mL
    10 mM 0.3469 mL 1.7346 mL 3.4692 mL 6.9384 mL 8.673 mL
    50 mM 0.0694 mL 0.3469 mL 0.6938 mL 1.3877 mL 1.7346 mL
    100 mM 0.0347 mL 0.1735 mL 0.3469 mL 0.6938 mL 0.8673 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Kinase Assay:
    Biochem Pharmacol. 2011 Feb 15;81(4):544-51.
    Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity.[Pubmed: 21087598 ]
    The transient potential vanilloid 1 receptor (TRPV1) is a calcium-permeable channel responsible for the transduction and modulation of acute and chronic pain signaling. As such, this receptor is a potential target for the treatment of a number of pain disorders. However, AMG517, a TRPV1 antagonist, presents several clinical limitations that include the induction of severe hyperthermia.
    The aim of this study was to investigate the possible interaction of the flavonoid Eriodictyol with the TRPV1 receptor and to determine its putative antinociceptive and hyperthermic effects. Eriodictyol was able to displace [(3)H]-resiniferatoxin binding (IC(50)=47; 21-119nM) and to inhibit calcium influx mediated by capsaicin (IC(50)=44; 16-125nM), suggesting that Eriodictyol acts as a TRPV1 antagonist. Moreover, Eriodictyol induced antinociception in the intraplantar capsaicin test, with maximal inhibition of 49±10 and 64±4% for oral (ID(50)=2.3; 1.1-5.7mg/kg) and intrathecal (ID(50)=2.2; 1.7-2.9nmol/site) administration, respectively. Eriodictyol did not induce any change in body temperature or locomotor activity. Orally administered Eriodictyol (4.5mg/kg) prevented the nociception induced by intrathecal injections of capsaicin, as well as the non-protein thiol loss and 3-nitrotyrosine (3-NT) formation induced by capsaicin in spinal cord. Eriodictyol also reduced the thermal hyperalgesia and mechanical allodynia elicited by complete Freund's adjuvant (CFA) paw injection.
    In conclusion, Eriodictyol acts as an antagonist of the TRPV1 receptor and as an antioxidant; it induces antinociception without some of the side effects and limitations such as hyperthermia that are expected for TRPV1 antagonists.
    J Biol Chem. 2011 Jan 21;286(3):2057-66.
    Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.[Pubmed: 21098035]
    RSK2 is a widely expressed serine/threonine kinase, and its activation enhances cell proliferation.
    Here, we report that ATF1 is a novel substrate of RSK2 and that RSK2-ATF1 signaling plays an important role in EGF-induced neoplastic cell transformation. RSK2 phosphorylated ATF1 at Ser-63 and enhanced ATF1 transcriptional activity. Docking experiments using the crystal structure of the RSK2 N-terminal kinase domain combined with in vitro pulldown assays demonstrated that Eriodictyol, a flavanone found in fruits, bound with the N-terminal kinase domain of RSK2 to inhibit RSK2 N-terminal kinase activity. In cells, Eriodictyol inhibited phosphorylation of ATF1 but had no effect on the phosphorylation of RSK, MEK1/2, ERK1/2, p38 or JNKs, indicating that Eriodictyol specifically suppresses RSK2 signaling. Furthermore, Eriodictyol inhibited RSK2-mediated ATF1 transactivation and tumor promoter-induced transformation of JB6 Cl41 cells. Eriodictyol or knockdown of RSK2 or ATF1 also suppressed Ras-mediated focus formation.
    Overall, these results indicate that RSK2-ATF1 signaling plays an important role in neoplastic cell transformation and that Eriodictyol is a novel natural compound for suppressing RSK2 kinase activity.
    Cell Research:
    J Agric Food Chem. 2012 Aug 8;60(31):7652-8.
    Effect of eriodictyol on glucose uptake and insulin resistance in vitro.[Pubmed: 22809065]
    Eriodictyol [2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one] is a flavonoid with anti-inflammatory and antioxidant activities.
    Because inflammation and oxidative stress play critical roles in the pathogenesis of diabetes mellitus, the present study was designed to explore whether Eriodictyol has therapeutic potential for the treatment of type 2 diabetes. The results show that Eriodictyol increased insulin-stimulated glucose uptake in both human hepatocellular liver carcinoma cells (HepG2) and differentiated 3T3-L1 adipocytes under high-glucose conditions. Eriodictyol also up-regulated the mRNA expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and adipocyte-specific fatty acid-binding protein (aP2) as well as the protein levels of PPARγ2 in differentiated 3T3-L1 adipocytes. Furthermore, it reactivated Akt in HepG2 cells with high-glucose-induced insulin resistance. This response was strongly inhibited by pretreatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, indicating that Eriodictyol increased Akt phosphorylation by activating the PI3K/Akt pathway.
    These results imply that Eriodictyol can increase glucose uptake and improve insulin resistance, suggesting that it may possess antidiabetic properties.
    Animal Research:
    Planta Med. 1999 Apr;65(3):234-8.
    Vasodilatory effect in rat aorta of eriodictyol obtained from Satureja obovata.[Pubmed: 10232068]

    The vasodilator effect of Eriodictyol (5,7,3',4'-tetrahydroxyflavanone), isolated previously from the medicinal plant Satureja obovata Lag., was studied in rat thoracic aorta rings. Eriodictyol relaxed in a concentration-dependent manner the noradrenaline (10(-6) M) and KCl (80 mM) induced contractions. The relaxant effect was more potent in noradrenaline precontracted preparations (IC50 = 6.11 +/- 0.2 x 10(-5) M) than in those precontracted with KCl (IC50 = 2.96 +/- 0.1 x 10(-4) M). Eriodictyol produced weakly concentration-dependent inhibition of the phasic component induced by KCl and noradrenaline while the inhibition of the tonic phase of these contractions was more pronounced. These effects were endothelium independent. In addition, Eriodictyol (10(-5) and 5 x 10(-5) M) inhibited CaCl2 cumulative concentration response curves. Eriodictyol weakly inhibited the release of calcium from the sarcoplasmic reticulum and its contribution to the relaxant effect seems to be slight. We have also observed the relaxant effect of Eriodictyol on phorbol-12-myristate-13-acetate (PMA) (10(-7) M) induced contractions both in normal calcium (IC50 = 4.69 +/- 0.3 x 10(-5) M) and calcium-free medium (IC50 = 3.74 +/- 0.4 x 10(-5) M). Finally we studied the effects on protein kinase C (PKC) activity.
    This flavonoid did not show any activity. These results suggest that the vasodilator effect of Eriodictyol in rat thoracic aorta could be partially related to the inhibition of calcium influx or other enzymatic protein subsequent to activation of PKC related to the activation of contractile proteins like myosin light chain kinase (MLCK).